- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
"Not So Different" Episode 4: Creating a Vibrant Biosimilars Marketplace
“We need all stakeholders to be all in on biosimilars…now’s the time for people to get engaged and get out there to support uptake and access,” says our guest, Juliana Reed, president of Biosimilars Forum.
Last week on the podcast, we brought you an industry perspective on biosimilars with a discussion of how manufacturers think about pricing their products for the marketplace. This week, we’re changing gears with a discussion of how that marketplace is working.
Our guest this week is Juliana Reed, president of Biosimilars Forum.
The Biosimilars Forum is a nonprofit organization that seeks to raise awareness of biosimilars and provide an opportunity for developers to work together with other stakeholders on relevant topics in the industry. The founding members of the Biosimilars Forum include many of the companies with significant US biosimilar development portfolios.
Reed joined The Center for Biosimilars® by phone to discuss reimbursement, policy, and what it takes to create a vibrant marketplace for cost-saving biosimilars.
Biosimilars Policy Roundup for March 2023—Podcast Edition
April 2nd 2023On this episode of Not So Different, we discuss some of the global biosimilar policy news that came out during the month of March, including a new bill in Congress and 2 Canadian jurisdictions implementing switching policies.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?
November 13th 2022Craig Burton, senior vice president of policy and strategic alliances at the Association for Accessible Medicines and executive director of the Biosimilars Council, gives insight into the many health policies that the Biden administration has implemented in 2022 as well as their possible impact on biosimilar adoption.
